Preparation method and application of nano antibiotic
By preparing nano-antibiotics using silver nanocubes and gold-silver alloy nanocage carriers, and combining them with photothermally induced release photosensitizers, the problems of complex and costly preparation of existing nano-antibiotics have been solved, achieving highly efficient killing of bacteria and rapid healing of chronic wounds.
Patent Information
- Application Number
- CN202411091665.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Existing nano-antibiotic preparation processes are complex and costly, and their antibacterial effects are unstable, making them difficult to effectively treat bacterial infections, especially chronic wounds.
Using silver nanocubes and gold-silver alloy nanocages as carriers, combined with photosensitizers and encapsulation layer molecules, the photosensitizers are released through photothermal induction, achieving efficient killing and imaging of various bacteria.
The prepared nano-antibiotics have broad-spectrum antibacterial properties, no drug resistance, can rapidly kill bacteria, promote inflammation reduction and tissue repair, and significantly accelerate the healing of chronic wounds.
Smart Images

Figure CN118987267A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of nano antibiotics, and specifically relates to a preparation method of nano antibiotics and application thereof. Background Art
[0002] In the medical field, bacterial infection and the complex wound problems caused by it have always been a severe challenge faced by clinicians. With the widespread use of antibiotics, the emergence and spread of drug-resistant strains has become a major problem in the global public health field. Traditional antibiotics are often limited by the limitations of their antibacterial spectrum when treating infections, and long-term use can easily lead to bacterial resistance, thereby reducing the treatment effect. For infected wounds, especially chronic wounds, such as diabetic foot ulcers and burn wounds, the treatment process is complicated and lengthy, and a new treatment method that can quickly control infection and promote wound healing is needed.
[0003] The rapid development of nanotechnology has provided a new idea for solving this problem. Nanomaterials have shown great potential in the field of antibacterial therapy due to their unique physical and chemical properties, such as high specific surface area, excellent permeability and controllable surface properties. In recent years, researchers have been committed to developing nanoantibiotics with broad-spectrum antibacterial properties, no drug resistance and good biocompatibility, in order to achieve efficient treatment of infected wounds. However, most of the nanoantibiotics on the market currently have problems such as complex preparation process, high cost, unstable antibacterial effect, etc., which are difficult to meet clinical needs. Therefore, it is of great significance to develop a nanoantibiotic that is simple to prepare, low cost and has significant antibacterial effect. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a preparation method and application of nano antibiotics in view of the deficiencies of the above-mentioned prior art. The nano antibiotics are essential for regulating the wound microenvironment, promoting inflammation regression and tissue repair, and can significantly accelerate the healing process of chronic wounds.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is: a method for preparing nano antibiotics, the method comprising:
[0006] S1. Preparation of silver nanocubes:
[0007] After heating ethylene glycol at a temperature of 140° C. to 150° C. for 1 hour, a sodium hydrosulfide solution with a concentration of 3 mM is added to the heated ethylene glycol, a hydrochloric acid solution with a concentration of 1 mM is added after 2 minutes, and then a polyvinyl pyrrolidone solution with a concentration of 13 mg / mL to 15 mg / mL is added, and a silver trifluoroacetate solution with a concentration of 282 mM is added after 2 minutes. After the reaction is completed, it is cooled in an ice water bath, and then centrifuged and washed twice with acetone and deionized water at a speed of 8000 r / min to 9000 r / min, respectively, to obtain silver nanocubes, which are dispersed in deionized water a to obtain a silver nanocube solution;
[0008] S2. Preparation of gold-silver alloy nanocages:
[0009] Under magnetic stirring at a temperature of 95° C., the silver nanocube solution obtained in S1 is added to a polyvinyl pyrrolidone aqueous solution with a concentration of 0.25 mg / mL to 1.5 mg / mL, and then a chloroauric acid solution with a concentration of 80 mg / mL is added dropwise. After the reaction is completed, the mixture is cooled in an ice water bath, and then centrifuged at a speed of 9000 r / min to 11000 r / min. The obtained precipitate is washed by centrifugation with a saturated sodium chloride solution, and then washed with deionized water for 3 times to obtain a gold-silver alloy nanocage, which is dispersed in deionized water b to obtain a gold-silver alloy nanocage solution;
[0010] S3. Preparation of Nanoantibiotics:
[0011] The gold-silver alloy nanocage solution obtained in S2 is centrifuged at a speed of 9000 r / min to 15000 r / min. After the supernatant is removed, a photosensitizer solution with a concentration of 0.1 mM is added, mixed evenly, and centrifuged to obtain a precipitate. The precipitate is dispersed with the coating layer molecules and centrifuged again. The precipitate obtained is the nanoantibiotic.
[0012] Preferably, the usage ratio of ethylene glycol, sodium hydrosulfide solution, hydrochloric acid solution, polyvinyl pyrrolidone solution, silver trifluoroacetate solution and deionized water a in S1 is 5 mL: (0.06-3) mL: (0.4-0.45) mL: (0.25-2.5) mL: 0.1 mL: 2 mL.
[0013] Preferably, the amount ratio of the silver nanocube solution, the polyvinyl pyrrolidone aqueous solution, the chloroauric acid solution and the deionized water b in S2 is 100 μL:10 mL:(0.5-10) mL:1 mL.
[0014] Preferably, the dropping speed in S2 is 1 mL / min to 1.5 mL / min.
[0015] Preferably, the photosensitizer in the photosensitizer solution in S3 includes TAP-Py or dihydrochlorin e6.
[0016] Preferably, the dosage ratio of the gold-silver alloy nanocage solution and the photosensitizer solution in S3 is 1 mL:2 mL.
[0017] Preferably, the coating layer molecules in S3 include 2% bovine serum albumin solution or dimyristoylphosphatidylcholine.
[0018] The present invention also provides the use of the nano antibiotic prepared by the above preparation method, wherein the nano antibiotic is used for sterilizing infectious wounds and promoting tissue healing and repair.
[0019] Compared with the prior art, the present invention has the following advantages:
[0020] The nano antibiotic prepared by the present invention has broad-spectrum antibacterial properties and no drug resistance. The nano antibiotic uses mesoporous photothermal nanoparticles as carriers, accurately controls the amount of photosensitizer loaded, and uses coating layer molecules for encapsulation, so as to achieve efficient killing of multiple bacteria and is not easy to produce drug resistance. In addition, the nano antibiotic can release photosensitizers and image bacteria under photothermal induction, which provides strong support for clinical diagnosis and treatment. More importantly, the nano antibiotic of the present invention has shown extremely significant positive effects in the treatment of infected wounds. It can not only kill pathogens quickly and efficiently, but also actively promote the polarization process of M2 macrophages, which is crucial for regulating the wound microenvironment, promoting inflammation regression and tissue repair. In addition, the nano antibiotic also significantly accelerates the healing process of chronic wounds, providing an innovative and effective solution for patients who have long been troubled by wound problems. The nano antibiotic prepared by the present invention has broad application prospects and important social value in the medical field.
[0021] The present invention is further described in detail below with reference to the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is the transmission electron microscope image of AuNCs in Example 1.
[0023] Figure 2 (A) is a transmission electron microscopy image of TAB NPs in Example 1.
[0024] Figure 2 (B) is the UV-visible spectrum of TAB NPs in Example 1.
[0025] Figure 2 (C) is the hydrodynamic size of the TAB NPs involved in Example 1.
[0026] Figure 2 (D) is the Zeta potential of the TAB NPs involved in Example 1.
[0027] Figure 2 (E) is the loading amount of TPA-Py measured in Example 1.
[0028] Figure 2 (F) is the power density of 0.8 W cm in Example 1. -2 Relative changes in fluorescence intensity of the mixture of DCFH-DA, AuNCs, TPA-Py, and TAB-NPs at 525 nm under 660 nm laser irradiation.
[0029] Figure 3 (A) is the TAB NPs in Example 1 at a wavelength of 660 nm and a power density of 0.8 W cm -2 Thermal imaging under laser.
[0030] Figure 3 (B) is the TAB NPs in Example 1 at a wavelength of 660 nm and a power density of 0.8 W cm -2 Temperature variation curve under laser.
[0031] Figure 3 (C) TAB NPs in Example 1 at different times (0.3 W cm -2 ) Fluorescence intensity of TPA-Py released after irradiation.
[0032] Figure 3 (D) TPA-Py released from TAB NPs in Example 1 was used to fluorescently label Staphylococcus aureus and Staphylococcus epidermidis.
[0033] The present invention Figure 4 (A) Evaluation of the antibacterial activity of Staphylococcus aureus treated with different concentrations of TPA-Py, AuNCs and TABNPs after incubation for 24 hours in Example 1
[0034] Figure 4 (B) Evaluation of the antibacterial activity of Escherichia coli treated with different concentrations of TPA-Py, AuNCs and TAB NPs in Example 1 after incubation for 24 hours.
[0035] Figure 4 (C) Quantitative analysis of the antibacterial effect of Staphylococcus aureus treated with different concentrations of TPA-Py, AuNCs and TAB NPs in Example 1.
[0036] Figure 4 (D) Quantitative analysis of the antibacterial effect of Escherichia coli treated with different concentrations of TPA-Py, AuNCs and TAB NPs in Example 1.
[0037] Figure 5 Scanning electron microscope images of Staphylococcus aureus and Escherichia coli after different treatments in Example 1. (AuNCs: 128 μg / mL, TPA-Py: 68.4 μg / mL, Au-containing TAB NPs: 128 μg / mL, TPA-Py: 68.4 μg / mL)
[0038] Figure 6 (A) is the survival rate of methicillin-resistant Staphylococcus aureus in Example 1 after incubation with TAB NPs (64 μg / mL, 128 μg / mL, 256 μg / mL) at different times.
[0039] Figure 6 (B) shows the changes in MIC values of Staphylococcus aureus and Escherichia coli after being co-incubated with TAB NPs for 12 generations in Example 1.
[0040] Figure 7 (A) is a digital image of the ablation of methicillin-resistant Staphylococcus aureus biofilm after adding PBS, AuNCs, TPA-Py and TAB NPs in Example 1 (AuNCs: 64 μg / mL, TPA-Py: 34.2 μg / mL, TAB NPs containing Au is 64 μg / mL)
[0041] Figure 7 (B) is the quantitative biofilm ablation percentage of different concentrations of TAB NPs in Example 1
[0042] Figure 8 (A) is the survival rate of L-929 cells with different concentrations of TAB NPs in Example 1
[0043] Figure 8 (B) shows the hemolysis of TAB NPs at different concentrations in Example 1.
[0044] Figure 8 (C) shows the hemolysis of TAB NPs observed with naked eyes in Example 1.
[0045] Fig. 9 (A) is a representative photo of the wound surface treated at different times in Example 1.
[0046] Fig. 9 (B) is the statistics of wound healing areas in different groups at different times in Example 1.
[0047] Fig. 9 (C) is a photo of bacterial colonies on the infected wound of rats treated in Example 1
[0048] Fig. 9(D) is the quantitative analysis result of the infected wound of rats treated with TPA-Py, AuNCs and TAB NPs in Example 1.
[0049] Fig. 9 (E) is the Giemsa staining result of different groups on day 7 in Example 1. Scale bar: 25 μm. (Black arrows indicate bacteria, N=3, mean±SD, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001) DETAILED DESCRIPTION
[0050] Example 1
[0051] The preparation method of the nano antibiotic of this embodiment is as follows:
[0052] S1. Preparation of silver nanocubes:
[0053] 5 mL of ethylene glycol was placed in a round-bottom flask, heated at 140°C for 1 h, and then excess water was removed. 2 mL of 3 mM sodium hydrosulfide solution was added to the heated ethylene glycol. 0.4 mL of 1 mM hydrochloric acid solution was added after 2 min, and then 0.25 mL of 13 mg / mL polyvinyl pyrrolidone solution was added. 0.1 mL of 282 mM silver trifluoroacetate solution was added after 2 min. The whole reaction was completed within 30 min. After the reaction was completed, the mixture was cooled in an ice water bath, and then centrifuged and washed twice with acetone and deionized water at a speed of 8000 r / min, respectively, to obtain silver nanocubes, which were dispersed in 2 mL of deionized water to obtain a silver nanocube solution.
[0054] The silver source in this embodiment can also be silver nitrate;
[0055] S2. Preparation of gold-silver alloy nanocages:
[0056] Under magnetic stirring at a temperature of 95°C, 100 μL of the silver nanocube solution obtained in S1 was added to 10 mL of a polyvinyl pyrrolidone aqueous solution with a concentration of 0.25 mg / mL, and then 0.5 mL of a chloroauric acid solution with a concentration of 80 mg / mL was added dropwise at a dropping speed of 1 mL / min to prepare a gold-silver alloy nanocage with UV-visible absorption at 660 nm; after the reaction was completed, the reaction solution was cooled in an ice water bath, and then centrifuged at a speed of 9000 r / min, and the obtained precipitate was centrifugally washed with a saturated sodium chloride solution to remove the silver chloride produced in the galvanic replacement reaction, and then washed with deionized water 3 times to remove the residual polyvinyl pyrrolidone in the solution to obtain a gold-silver alloy nanocage, which was dispersed in 1 mL of deionized water b to obtain a gold-silver alloy nanocage solution;
[0057] The prepared gold-silver alloy nanocages exhibit strong absorption and scattering capabilities at specific wavelengths. The position of their SPR peak can be transformed from the visible light region to the near-infrared region by regulating the size and porosity of the gold nanocages and has strong photothermal conversion properties.
[0058] like Figure 1 As shown, the hollow, porous structure of the gold-silver alloy nanocage enables it to carry molecules such as drugs and fluorescent dyes.
[0059] Gold-silver alloy nanocages have good stability and dispersibility in aqueous solution and are not easy to aggregate and precipitate.
[0060] The surface of gold-silver alloy nanocages can be easily further functionalized to achieve customization and optimization by introducing specific functional groups or biomolecules.
[0061] S3. Preparation of Nanoantibiotics:
[0062] The gold-silver alloy nanocage solution obtained in 1 mL of S2 was centrifuged at a speed of 9000 r / min. After the supernatant was removed, 2 mL of a 0.1 mM photosensitizer (TAP-Py molecule) solution was added and mixed evenly. The precipitate was obtained by centrifugation and dispersed with 2 mL of a 2% bovine serum albumin solution (BSA) of the coating layer molecule. The precipitate was centrifuged again to obtain the nanoantibiotic (named TAB NPs).
[0063] The encapsulating layer molecules used in this embodiment include but are not limited to bovine serum albumin, and may also be organic materials such as polysaccharides, phospholipids, silica, etc., inorganic materials or biological materials.
[0064] The photosensitizer in this embodiment can generate significant active oxygen and has strong photostability.
[0065] The nano antibiotic prepared in this embodiment can release the photosensitizer under light induction, and the released photosensitizer can infect bacteria and realize bacterial fluorescence imaging.
[0066] The nano antibiotics prepared in this example are used to sterilize infectious wounds and promote tissue healing and repair.
[0067] The absorption spectrum information of nanoantibiotics was measured using a UV-visible spectrophotometer.
[0068] Particle size and zeta potential were measured by dynamic light scattering.
[0069] Figure 2 A is a transmission electron microscope image of the nanoantibiotic. Figure 2 B is the UV-visible spectrum peak of the nanoantibiotic.
[0070] like Figure 2 As shown in C, the hydrodynamic size of the nanoantibiotic is 67.2±6.6nm.
[0071] like Figure 2 As shown in D, the corresponding Zeta potential of the nanoantibiotic is -14.1 mV.
[0072] (I) The nanoantibiotic prepared in this example is loaded with TPA-Py:
[0073] The concentration of TPA-Py was quantitatively determined by fluorescence spectroscopy (HORIBA, FRANSE, FLOROMAX-4) with an emission wavelength of 670 nm and an excitation wavelength of 565 nm and compared with a pre-established calibration curve.
[0074] like Figure 2 As shown in Figure E, with the increase of TPA-Py concentration, the loading amount of the nanoantibiotic showed an upward trend.
[0075] (ii) The reactive oxygen species (ROS) producing ability of the nanoantibiotics prepared in this example was tested.
[0076] 2',7'-dichlorofluorescein diacetate (DCFH-DA) method for detecting total ROS: First, 0.5 mL of DCFH-DA (1 mM) in ethanol was added to 2 mL of sodium hydroxide solution and stirred at room temperature for 30 minutes to hydrolyze DCFH-DA into 2',7'-dichlorodihydrofluorescein (DCFH). Then, DCFH was neutralized with 10 mL of phosphate buffered saline (pH = 7.4) and stored in the dark. The prepared DCFH solution was added to the sample solutions of TPA-Py, gold-silver alloy nanocages and nanoantibiotics. Subsequently, a laser (660 nm, 0.8 W cm -2 ) irradiated the mixed solution at different time intervals. The fluorescence intensity of the indicator with an emission wavelength of 525 nm was measured on a photoluminescence instrument with an excitation wavelength of 488 nm.
[0077] like Figure 2 As shown in Figure 5, in the TAB NPs system, the fluorescence intensity continued to increase under laser irradiation, and reached a peak after about 9 minutes.
[0078] (III) Photothermal properties of the nanoantibiotics prepared in this example and the drug release conditions.
[0079] 1. Photothermal properties of nanoantibiotics:
[0080] The nanoantibiotics were tested with a wavelength of 660 nm and a power density of 0.8 W cm -2During the irradiation process, a thermal imager was used to monitor and record the temperature changes of the sample solution in real time.
[0081] like Figure 3 As shown in A, the results show that the nanoantibiotic has an excellent photothermal effect, which is consistent with the photothermal curve results ( Figure 3 B) consistent.
[0082] 2. Release of TPA-Py from Nanoantibiotics:
[0083] The nanoantibiotic solution was diluted with phosphate buffered saline to a final concentration of 5 μM TPA-Py in a 1.5 mL test tube. Subsequently, the nanoantibiotic was irradiated with laser light at different time intervals.
[0084] Under laser irradiation, the nanoantibiotic successfully released TPA-Py, and the fluorescence intensity was Figure 2 As shown in C.
[0085] like Figure 3 As shown in D, TPA-Py released from TAB NPs can effectively fluorescently label Staphylococcus aureus and Staphylococcus epidermidis, but has no effect on Escherichia coli. The results show that the TPA-Py photosensitizer can penetrate Gram-positive bacteria, but is blocked by the outer membrane of Gram-negative bacteria, making it difficult for TPA-Py to penetrate.
[0086] (IV) Study on the antibacterial properties of the nanoantibiotics prepared in this example.
[0087] Con(+) group was the blank control group under laser irradiation;
[0088] The TPA-Py(+) group was TPA-Py alone under laser irradiation;
[0089] The AuNCs(+) group was AuNCs alone under laser irradiation;
[0090] The TAB NPs (+) group was TAB NPs alone under laser irradiation;
[0091] The TAB NPs(-) group was TAB NPs alone without laser irradiation;
[0092] 1. Bacterial resistance assessment:
[0093] Escherichia coli and Staphylococcus aureus were prepared with phosphate buffered saline (PBS) at a concentration of 10 5 CFU / mL of bacterial suspension, and then mixed with antimicrobial materials with concentrations ranging from 0 to 128 μg / mL in a 96-well plate. The irradiation group used a wavelength of 660 nm and a power density of 0.8 W cm -2The laser was irradiated for 10 minutes. Each group was then cultured for 4 hours at 37°C with slight shaking. After culture, the bacterial solution was diluted 10 times with PBS. 20 μL of the dilution was spread on LuriaBertani (LB) agar solid medium and incubated at 37°C. After 24 hours, the bacterial colonies formed on the plate were analyzed.
[0094] Depend on Figure 4 A and Figure 4 Bacterial plate counts showed that TAB NPs had significant antibacterial activity, with a bactericidal efficacy of more than 99% against Staphylococcus aureus and Escherichia coli at a concentration of 64 μg / ml. At this concentration, TPA-Py alone (72.1% survival rate for Staphylococcus aureus and 98.7% survival rate for Escherichia coli) or AuNCs (64.6% survival rate for Staphylococcus aureus and 45.3% survival rate for Escherichia coli) could not effectively eliminate bacteria ( Figure 4 C and Figure 4 D)
[0095] 2. Morphological analysis:
[0096] Escherichia coli and Staphylococcus aureus were incubated with PBS (control group), TPA-Py (68.4 μg / mL), AuNCs (128 μg / mL), and TAB NPs (AuNCs and TPA-Py were 128 μg / mL and 68.4 μg / mL, respectively) for 10 min. Subsequently, the two bacterial suspensions were irradiated at a wavelength of 660 nm and a power density of 0.8 W cm -2 The samples were irradiated with laser for 10 min. Then, the bacterial mixture was washed several times by centrifugation and fixed with 2.5% glutaraldehyde at 4 °C overnight. After fixation, the bacteria were dehydrated through a series of ethanol concentrations ranging from 10% to 100%. Finally, gold was sputter-coated on the samples and characterized using scanning electron microscopy.
[0097] like Figure 5 As shown in the figure, the bacterial surface of the control group was smooth and the structure was intact. In contrast, the bacterial surface of the TPA-Py group and the AuNCs group was concave and deformed (yellow arrow), while the bacterial surface of the TAB NPs group was collapsed and broken (red arrow).
[0098] 3. Antibacterial kinetics experiment:
[0099] Methicillin-resistant Staphylococcus aureus was cultured in LB medium until the logarithmic growth phase (10 6 CFU / mL), and then mixed with different concentrations of TAB NPs solution and incubated at 37 °C for 1 h. After incubation, the cells were heated at a wavelength of 660 nm and a power density of 0.8 W cm -2The cells were irradiated with laser for 10 minutes, and 20 μL of bacterial solution was aspirated at different time points and diluted 10 times with PBS, evenly spread on LB agar solid culture medium, and cultured for 24 hours to evaluate the dynamic antibacterial effect of TAB NPs.
[0100] like Figure 6 As shown in A, for methicillin-resistant Staphylococcus aureus, when the concentration of TAB NPs was 64 μg / mL, about 40.8% of the bacteria were eliminated within 2 hours, and when the concentration was 256 μg / mL, the bactericidal efficiency was close to 95.3%
[0101] 4. Bacterial resistance assessment:
[0102] Staphylococcus aureus and Escherichia coli were cultured to the logarithmic growth phase. Then they were diluted to a concentration of 10 5 CFU / mL and co-cultured with TAB NPs to determine the minimum inhibitory concentration (MIC) of TAB NPs against Staphylococcus aureus and Escherichia coli. This process was repeated for 12 generations of bacteria, and the MIC value of TAB NPs against each generation of Staphylococcus aureus was recorded.
[0103] like Figure 6 As shown in (B), despite 12 generations of culture, the MIC values of TAB NPs against S. aureus and E. coli remained stable, indicating that continuous use of TAB NPs would not induce drug resistance in S. aureus and E. coli.
[0104] 5. Bacterial biofilm experiment:
[0105] 1mL of a concentration of 10 8 A suspension of methicillin-resistant Staphylococcus aureus (MRSA) at 37°C (CFU / mL) was cultured for 5 days at 37°C to form a static biofilm. After 5 days, the culture medium was removed and the 96-well plate was rinsed with PBS solution. Subsequently, TAB NPs were added. After a 10-minute irradiation period and a subsequent 12-hour incubation period, the efficacy of TAB NPs on MRSA biofilm was studied. Subsequently, the 96-well plate was washed with PBS and stained with 0.1% (w / v) crystal violet (CV) for 15 minutes, followed by rinsing with PBS to remove excess dye. 30% acetic acid was added to dissolve the CV on the stained biofilm, and finally the absorbance was measured at a wavelength of 595nm to quantify the biofilm.
[0106] like Figure 7 As shown in A, after a 10-minute irradiation period and a 12-hour incubation period, the exopolysaccharide in the biofilm was stained with crystal violet dye to quantify the biofilm content. Figure 7 B), its ablation efficiency of biofilm is significantly improved.
[0107] (V) Using bacterial toxicity test and hemolytic test to study the biocompatibility of the nanoantibiotic prepared in Example 1
[0108] 1. Cytotoxicity study:
[0109] Cell counting kit-8 (CCK-8) was used to evaluate the cell viability of nanoantibiotics according to the protocol provided by the manufacturer. L-929 cells were used as the research object and were purchased from the Chinese Academy of Sciences. L-929 cells were cultured in DMEM culture medium supplemented with 10% fetal bovine serum, penicillin and streptomycin and stored at 37°C and 5% CO2 until the cell confluence rate was 80%. Nanoantibiotics were incubated with L-929 cells for 24 hours, and specimens treated with phosphate buffered saline were used as the control group. After incubation for 24 hours, the CCK-8 method was used for subsequent toxicity evaluation.
[0110] like Figure 8 As shown in A, the results showed that after cells were cultured with different concentrations of TAB NPs for 24 h, the cell viability was 90.6% and no obvious cytotoxicity was observed even at a high concentration of 128 μg / mL.
[0111] 2. Hemolytic activity test:
[0112] Prepare a 2% red blood cell suspension, and then prepare 6 labeled 2 ml test tubes, where test tube No. 1 is used as a positive control for complete hemolysis, test tube No. 2 is used as a negative control, and test tubes No. 3 to 6 are designated for testing samples of different concentrations. Then add an equal volume of 2% red blood cell suspension to each test tube and incubate in a 65°C water bath. After incubation for 3 hours, measure and record the absorbance of the solution in each test tube at a wavelength of 540nm.
[0113] like Figure 8 As shown in B, after 2 hours of co-culture, less than 5% of the erythrocyte membranes were ruptured. Figure 8 As shown in Figure C, the color of the samples in the experimental group remained transparent after centrifugation compared with the control group. This observation indicates that TAB NPs have good blood compatibility.
[0114] (VI) In vivo study on chronic wound healing was conducted using the nanoantibiotic prepared in Example 1.
[0115] In vivo studies of chronic wound healing:
[0116] The animal experiment protocol was approved by the Biomedical Research Ethics Committee of Central South University. Forty male SD rats aged 8 weeks were used for the chronic wound healing experiment. After the rats were anesthetized and depilated, an infected skin defect model was established. The wound surface diameter was about 15 mm. The concentration of methicillin-resistant Staphylococcus aureus injected was 105 CFU / mL, 24 hours later, 100 μL of TAB NPs was sprayed on the defect site, followed by a 660 nm, 0.8 W cm -2 The rats were irradiated with near infrared light for 10 minutes. This step was repeated on the third day. Each rat was caged individually and photographed at specific time points to study the healing of chronic wounds by the change in wound area. Tissue samples excised from the wounds were fixed with 4% paraformaldehyde fixative and sections were stained. Plate culture and Giemsa staining were used to evaluate the residual bacteria in the wounds.
[0117] Con(+) group was the blank control group under laser irradiation;
[0118] The TPA-Py(+) group was TPA-Py alone under laser irradiation;
[0119] The AuNCs(+) group was AuNCs alone under laser irradiation;
[0120] The TAB NPs (+) group was TAB NPs alone under laser irradiation;
[0121] The TAB NPs(-) group was TAB NPs alone without laser irradiation;
[0122] like Fig. 9 A and Fig. 9 As shown in Figure 2, there was no significant difference in the wound area of each group on day 1. By day 3, the wound area of all groups had decreased, with the wound area of the TAB NPs(+) group being 54.1±3.5%, significantly lower than that of the other four groups, including 86.3±2.5% in the Con(+) group, 81.5±1.5% in the TPA-Py(+) group, 64.2±4.5% in the AuNCs(+) group, and 79.7±1.7% in the TAB NPs(-) group. By day 7, the wound area of the AuNCs(+) group was 32.7±2.1%, lower than that of the Con(+), TPA-Py(+), and TAB NPs(-) groups. At this time, the wound area of the TAB NPs(+) group was 13.9±4.9%, and the wound was almost healed and covered by new epithelial tissue. By day 14, the wound of the TAB NPs(+) group was almost completely healed, with a wound area of 1.5±0.4%. To demonstrate the infection around the wound on day 7, bacterial counts were obtained using the plate spread method ( Fig. 9 C) and analyzed ( Fig. 9 D). The results showed that no obvious colonies were observed in the TAB NPs(+) group, and the antibacterial effect was significantly better than that of the other four groups. To further demonstrate the antibacterial effect of TAB NPs, Giemsa staining was performed. Representative images of each group ( Fig. 9E) shows that there is no obvious bacterial colony in the TAB NPs(+) group, which is consistent with the plate results. Bacterial plate culture and Giemsa staining showed that there was no obvious colony in the TAB NPs(+) group, while there were obvious bacterial colonies in the AuNCs(+) and TPA-Py(+) groups, indicating that the synergistic antibacterial effect was very obvious.
[0123] The nanoantibiotics prepared in this embodiment have multiple functions, including but not limited to photothermal antibacterial, broad-spectrum dynamic antibacterial, physical and mechanical destruction of bacterial cell membranes, inhibition of bacterial protein synthesis, etc.
[0124] The nano antibiotic prepared in this embodiment can effectively kill bacteria without inducing bacterial resistance, wherein the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) will not change.
[0125] The nanoantibiotic prepared in this example can achieve bacterial biofilm ablation.
[0126] The nano antibiotics prepared in this embodiment can be directly used in the treatment of infectious wounds to achieve effective sterilization and promote rapid tissue healing and repair.
[0127] Example 2
[0128] The preparation method of the nano antibiotic of this embodiment is as follows:
[0129] S1. Preparation of silver nanocubes:
[0130] 5 mL of ethylene glycol was placed in a round-bottom flask, heated at 150°C for 1 h, and then excess water was removed. 0.06 mL of 3 mM sodium hydrosulfide solution was added to the heated ethylene glycol. After 2 min, 0.45 mL of 1 mM hydrochloric acid solution was added, and then 2.5 mL of 15 mg / mL polyvinyl pyrrolidone solution was added. After 2 min, 0.1 mL of 282 mM silver trifluoroacetate solution was added. The whole reaction was completed within 30 min. After the reaction was completed, the mixture was cooled in an ice water bath, and then centrifuged and washed twice with acetone and deionized water at a speed of 9000 r / min, respectively, to obtain silver nanocubes, which were dispersed in 2 mL of deionized water to obtain a silver nanocube solution.
[0131] S2. Preparation of gold-silver alloy nanocages:
[0132] Under magnetic stirring at a temperature of 95°C, 100 μL of the silver nanocube solution obtained in S1 was added to 10 mL of a polyvinyl pyrrolidone aqueous solution with a concentration of 0.25 mg / mL, and then 0.5 mL of a chloroauric acid solution with a concentration of 80 mg / mL was added dropwise at a dropping speed of 1 mL / min to prepare a gold-silver alloy nanocage with UV-visible absorption at 660 nm; after the reaction was completed, the reaction solution was cooled in an ice water bath, and then centrifuged at a speed of 9000 r / min, and the obtained precipitate was centrifugally washed with a saturated sodium chloride solution to remove the silver chloride produced in the galvanic replacement reaction, and then washed with deionized water 3 times to remove the residual polyvinyl pyrrolidone in the solution to obtain a gold-silver alloy nanocage, which was dispersed in 1 mL of deionized water b to obtain a gold-silver alloy nanocage solution;
[0133] S3. Preparation of Nanoantibiotics:
[0134] The gold-silver alloy nanocage solution obtained in 1 mL of S2 was centrifuged at a speed of 9000 r / min. After the supernatant was removed, 2 mL of a 0.1 mM photosensitizer dihydrochlorin e6 (Ce6) solution was added, mixed evenly, and centrifuged to obtain a precipitate. The precipitate was dispersed with 2 mL of a 2% bovine serum albumin solution (BSA) of the coating layer molecule, and centrifuged again to obtain a precipitate that was the nanoantibiotic.
[0135] The nano antibiotics prepared in this example are used to sterilize infectious wounds and promote tissue healing and repair.
[0136] Example 3
[0137] The preparation method of the nano antibiotic of this embodiment is as follows:
[0138] S1. Preparation of silver nanocubes:
[0139] 5 mL of ethylene glycol was placed in a round-bottom flask, heated at 150°C for 1 h, and then excess water was removed. 3 mL of 3 mM sodium hydrosulfide solution was added to the heated ethylene glycol. After 2 min, 0.45 mL of 1 mM hydrochloric acid solution was added, and then 2.5 mL of 13 mg / mL polyvinyl pyrrolidone solution was added. After 2 min, 0.1 mL of 282 mM silver trifluoroacetate solution was added. The whole reaction was completed within 30 min. After the reaction was completed, the mixture was cooled in an ice water bath, and then centrifuged and washed twice with acetone and deionized water at a speed of 9000 r / min, respectively, to obtain silver nanocubes, which were dispersed in 2 mL of deionized water to obtain a silver nanocube solution.
[0140] S2. Preparation of gold-silver alloy nanocages:
[0141] Under magnetic stirring at a temperature of 95° C., 100 μL of the silver nanocube solution obtained in S1 was added to 10 mL of a 1.5 mg / mL polyvinyl pyrrolidone aqueous solution, and then 10 mL of a 80 mg / mL chloroauric acid solution was added dropwise at a dropping speed of 1.5 mL / min to prepare a gold-silver alloy nanocage with UV-visible absorption at 660 nm; after the reaction was completed, the reaction solution was cooled in an ice water bath, and then centrifuged at a speed of 11000 r / min, and the obtained precipitate was centrifugally washed with a saturated sodium chloride solution to remove the silver chloride produced in the galvanic replacement reaction, and then washed with deionized water for 3 times to remove the residual polyvinyl pyrrolidone in the solution to obtain a gold-silver alloy nanocage, which was dispersed in 1 mL of deionized water b to obtain a gold-silver alloy nanocage solution;
[0142] S3. Preparation of Nanoantibiotics:
[0143] The gold-silver alloy nanocage solution obtained in 1 mL of S2 was centrifuged at a speed of 15000 r / min. After the supernatant was removed, 2 mL of a photosensitizer (TAP-Py molecule) solution with a concentration of 0.1 mM was added, mixed evenly, and centrifuged to obtain a precipitate. The precipitate was dispersed with 2 mL of a coating molecule, dimyristoylphosphatidylcholine (DMPC), and centrifuged again. The precipitate obtained was the nanoantibiotic.
[0144] The nano antibiotics prepared in this example are used to sterilize infectious wounds and promote tissue healing and repair.
[0145] The above is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent change made to the above embodiment according to the technical essence of the invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. A method for preparing a nano antibiotic, characterized in that: The method is: S1. Preparation of silver nanocubes: After heating ethylene glycol at a temperature of 140° C. to 150° C. for 1 hour, a sodium hydrosulfide solution with a concentration of 3 mM is added to the heated ethylene glycol, a hydrochloric acid solution with a concentration of 1 mM is added after 2 minutes, and then a polyvinyl pyrrolidone solution with a concentration of 13 mg / mL to 15 mg / mL is added, and a silver trifluoroacetate solution with a concentration of 282 mM is added after 2 minutes. After the reaction is completed, it is cooled in an ice water bath, and then centrifuged and washed twice with acetone and deionized water at a speed of 8000 r / min to 9000 r / min, respectively, to obtain silver nanocubes, which are dispersed in deionized water a to obtain a silver nanocube solution; S2. Preparation of gold-silver alloy nanocages: Under magnetic stirring at a temperature of 95° C., the silver nanocube solution obtained in S1 is added to a polyvinyl pyrrolidone aqueous solution with a concentration of 0.25 mg / mL to 1.5 mg / mL, and then a chloroauric acid solution with a concentration of 80 mg / mL is added dropwise. After the reaction is completed, the mixture is cooled in an ice water bath, and then centrifuged at a speed of 9000 r / min to 11000 r / min. The obtained precipitate is washed by centrifugation with a saturated sodium chloride solution, and then washed with deionized water for 3 times to obtain a gold-silver alloy nanocage, which is dispersed in deionized water b to obtain a gold-silver alloy nanocage solution; S3. Preparation of Nanoantibiotics: The gold-silver alloy nanocage solution obtained in S2 is centrifuged at a speed of 9000 r / min to 15000 r / min. After the supernatant is removed, a photosensitizer solution with a concentration of 0.1 mM is added, mixed evenly, and centrifuged to obtain a precipitate. The precipitate is dispersed with coating molecules and centrifuged again. The precipitate obtained is the nanoantibiotic.
2. The method for preparing a nano antibiotic according to claim 1, characterized in that: The dosage ratio of ethylene glycol, sodium hydrosulfide solution, hydrochloric acid solution, polyvinyl pyrrolidone solution, silver trifluoroacetate solution and deionized water a described in S1 is 5mL: (0.06-3)mL: (0.4-0.45)mL: (0.25-2.5)mL: 0.1mL: 2mL.
3. The method for preparing a nano antibiotic according to claim 1, characterized in that: The amount ratio of the silver nanocube solution, polyvinyl pyrrolidone aqueous solution, chloroauric acid solution and deionized water b in S2 is 100 μL:10 mL:(0.5-10) mL:1 mL.
4. The method for preparing a nano antibiotic according to claim 1, characterized in that: The dropping speed in S2 is 1 mL / min to 1.5 mL / min.
5. The method for preparing a nano antibiotic according to claim 1, characterized in that: The photosensitizer in the photosensitizer solution in S3 includes TAP-Py or dihydrochlorin e6.
6. The method for preparing a nano antibiotic according to claim 1, characterized in that: The dosage ratio of the gold-silver alloy nanocage solution and the photosensitizer solution in S3 is 1 mL:2 mL.
7. The method for preparing a nano antibiotic according to claim 1, characterized in that: The coating molecules in S3 include 2% bovine serum albumin solution or dimyristoylphosphatidylcholine.
8. An application of a nano antibiotic prepared by the preparation method according to any one of claims 1 to 7, characterized in that: The nano antibiotic is used for sterilizing infectious wounds and promoting tissue healing and repair.
Citation Information
Cited By
Spatial separation double-layer hydrogel as well as preparation method and application thereof
CN120227462A
